Supplementary information for:

Analysis of the potential for point-of-care test to enable individualised treatment of infections caused by antimicrobial-resistant and susceptible strains of *Neisseria* gonorrhoeae

Katy ME Turner, Hannah Christensen, Elisabeth J Adams, David McAdams, Helen Fifer, Anthony McDonnell, Neil Woodford

Table A1 Current prevalence of antimicrobial resistance to potential treatments for gonorrhoea

Drug	Class	Prevalence of resistance in GRASP 2014 isolates ¹					
		Heterosexual	MSM	Women	Overall		
		men					
Ceftriaxone Cephalosporin (3 rd generation)		0	0	0	0		
Penicillin	β-lactam	18%	26%	10%	23%		
Ciprofloxacin	Fluoroquinolone	28%	44%	15%	37%		
Azithromycin	Macrolide	0.0%	1.4%	0.5%	1.0%		

2 Table A2 Model parameters

Baseline model parameters		Current			AMR POCT	
	Heterosexual	MSM	Women	Heterosexual	MSM	Women
	men			men		
Initial population size ²	515,094	145,863	779,085	515,094	145,863	779,085
Proportion entering same day management pathway	35%	33%	48%	100%	100%	100%
Proportion infected with gonorrhoea (of total tested) ²	1.5%	12.4%	1.1%	1.5%	12.4%	1.1%
Proportion of those in same day pathway infected with gonorrhoea	3.1%	26.0%	1.0%	1.5%	12.4%	1.1%
Proportion of delayed management infected with gonorrhoea	0.7%	5.6%	1.2%	-	-	-
Relative risk infection gonorrhoea in same day vs delayed pathway	4.52	4.63	0.82	-	-	-
Proportion in same day pathway who are infected & treated on same day	96%	90%	50%	100%	100%	100%
Proportion of same day pathway treated presumptively for gonorrhoea	5.0%	25.0%	2.0%	1.5%	12.4%	1.1%
Proportion who attend for treatment after lab test result (of those who	95%	95%	95%	100%	100%	100%
wait for lab test results, i.e. asymptomatic group)						
Proportion treated with last line therapy ³	100%	100%	100%	28%ª	44% ^a	15%ª
Cost of first attendance ⁴⁵	£135	£135	£135	£135	£135	£135
Cost of follow-up attendance ^{4 5}	£104	£104	£104	£104	£104	£104


AMR POCT, antimicrobial resistance point of care test; MSM, men who have sex with men.

^aAssuming POCT for ciprofloxacin susceptibility (can be adjusted for penicillin according to parameters in Table A1 or updated to reflect local trends)


3 4 5

1 Figure A1


2 **A – Heterosexual men current pathway**



B – Heterosexual men POCT pathway




1 **C** – Women current pathway



Page 5 of 7

1 **D – Women new pathway**



1 References

- 1 Adams EJ, Ehrlich A, Turner KM, Shah K, Macleod J, Goldenberg S, et al. Mapping patient
- 3 pathways and estimating resource use for point of care versus standard testing and
- treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK. BMJ
 Open 2014: 4(7): e005322.
- 2 Public Health England. STI diagnoses & rates by gender, sexual risk & age group, 2010 2014, 2015.
- 8 3 England. PH. Surveillance of antimicrobial resistance in *Neisseria gonorrhoeae*. Key
- 9 findings from the 'Gonococcal resistance to antimicrobials surveillance programme'
- 10 (GRASP) and related surveillance data, 2014.
- 4 Monitor and NHS England. 2014/15 National Tariff Payment System, 2013.
- 12 5 Health PHEatDo. HIV, sexual and reproductive health: current issues bulletin2013.
- 13 Available from:
- <u>https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/259087/HIV_S</u>
 exual and Reproductive Health bulletin-issue1nov2013.pdf.
- 6 Turner KM, Round J, Horner P, Macleod J, Goldenberg S, Deol A, et al. An early
- evaluation of clinical and economic costs and benefits of implementing point of care NAAT
- tests for *Chlamydia trachomatis* and *Neisseria gonorrhoea* in genitourinary medicine clinics
- in England. Sex Transm Infect 2014; 90(2): 104-11.
- 20